Compounds > etomoxir
Page last updated: 2024-09-03

etomoxir and Colonic Neoplasms

etomoxir has been researched along with Colonic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Al-Khami, AA; Hernandez, C; Hossain, F; Maj, T; Ochoa, AC; Reiss, K; Rodriguez, PC; Trillo-Tinoco, J; Valle, LD; Wyczechowska, D; Zheng, L; Zou, W1
Ates, YO; Hernlund, E; Ihrlund, LS; Khan, O; Linder, S; Panaretakis, T; Shoshan, MC1

Other Studies

2 other study(ies) available for etomoxir and Colonic Neoplasms

ArticleYear
Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
    Cancer immunology research, 2015, Volume: 3, Issue:11

    Topics: Animals; Antineoplastic Agents; Antioxidants; Colonic Neoplasms; Combined Modality Therapy; Drug Evaluation, Preclinical; Energy Metabolism; Epoxy Compounds; Fatty Acids; Female; Humans; Immune Tolerance; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Myeloid Cells; Oxidation-Reduction; Tumor Microenvironment

2015
Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir.
    International journal of cancer, 2008, Jul-15, Volume: 123, Issue:2

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Cisplatin; Colonic Neoplasms; Deoxyglucose; Drug Screening Assays, Antitumor; Drug Synergism; Energy Metabolism; Epoxy Compounds; HCT116 Cells; Humans; Oxidation-Reduction; Reactive Oxygen Species; Time Factors

2008